title: Esomeprazole versus pantoprazole for healing erosive oesophagitis.
abstract: The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to healing and relief from gastroesophageal reflux disease-related symptoms. I this multicentre, randomized, single-blind study 180 patients (ITT population) diagnosed with endoscopically proven GERD grade A,B,C received esomeprazole (40 mg once daily (o.d.), n = 90) orpantoprazole (40 mg o.d., n = 90). Healing and relief from GERD-related symptoms were assessed at first and final visit (after 4 or 8 weeks of treatment). Esomeprazole 40 mg provided significantly greater healing than pantoprazole 40 mg after 4 weeks of treatment in patients with EE (77.8% vs. 72.2%). Esomeprazole-treated patients were healed after up to 8 weeks of treatment similar those treated with pantoprazole (92.2% vs. 91.1%). The proportion of heartburn-free days was similar in patients treated with esomeprazole and to those treated with pantoprazole.
authors.affiliation: Department of Internal Medicine, School of Medicine, University J.J. Strossmayer, Osijek, Croatia. vcev.aleksandar@kbo.hr
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Vcev
authors.forename: Ivana
authors.initials: I
authors.lastname: Begić
authors.forename: Rajko
authors.initials: R
authors.lastname: Ostojić
authors.forename: Dragan
authors.initials: D
authors.lastname: Jurcić
authors.forename: Dubravko
authors.initials: D
authors.lastname: Bozić
authors.forename: Ivan
authors.initials: I
authors.lastname: Soldo
authors.forename: Rudika
authors.initials: R
authors.lastname: Gmajnić
authors.forename: Goran
authors.initials: G
authors.lastname: Kondza
authors.forename: Eyad
authors.initials: E
authors.lastname: Khaznadar
authors.forename: Nikola
authors.initials: N
authors.lastname: Mićunović
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D064098:Esomeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D012720:Severity of Illness Index; D013454:Sulfoxides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D000077402:Pantoprazole; D064098:Esomeprazole